| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2013PLoSO...881768G |
| P356 | DOI | 10.1371/JOURNAL.PONE.0081768 |
| P932 | PMC publication ID | 3842420 |
| P698 | PubMed publication ID | 24312353 |
| P5875 | ResearchGate publication ID | 259208920 |
| P2093 | author name string | Li Li | |
| Kevin A Cassady | |||
| Richard J Whitley | |||
| Justin C Roth | |||
| James M Markert | |||
| Jacqueline N Parker | |||
| David C Gaston | |||
| Carl I Odom | |||
| P2860 | cites work | Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15 | Q24301975 |
| Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor | Q24323032 | ||
| IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells | Q28214975 | ||
| The 5' untranslated region, signal peptide, and the coding sequence of the carboxyl terminus of IL-15 participate in its multifaceted translational control | Q28269992 | ||
| Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame | Q28483092 | ||
| Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. | Q51332049 | ||
| Regulation of IL-15 secretion via the leader peptide of two IL-15 isoforms | Q71929898 | ||
| The long signal peptide isoform and its alternative processing direct the intracellular trafficking of interleukin-15 | Q73929921 | ||
| Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma | Q84834335 | ||
| Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice | Q28594052 | ||
| HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival | Q30954768 | ||
| Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis | Q33675567 | ||
| Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM | Q33712977 | ||
| Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo | Q33760403 | ||
| Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses | Q33773376 | ||
| Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma | Q33905047 | ||
| Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial | Q33905053 | ||
| IL-15 mimics T cell receptor crosslinking in the induction of cellular proliferation, gene expression, and cytotoxicity in CD8+ memory T cells | Q34028468 | ||
| The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study | Q34124333 | ||
| ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties | Q34178661 | ||
| Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1 | Q34302130 | ||
| Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins | Q34463480 | ||
| Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy | Q34496174 | ||
| A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. | Q34583808 | ||
| Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma | Q34616722 | ||
| Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha} | Q34694913 | ||
| Characterization and favorable in vivo properties of heterodimeric soluble IL-15·IL-15Rα cytokine compared to IL-15 monomer | Q34708192 | ||
| Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma | Q34794313 | ||
| Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models | Q34988018 | ||
| Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques | Q35001598 | ||
| Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses | Q35036505 | ||
| Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors | Q35051285 | ||
| Distinguishing inflammation from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging. | Q35091322 | ||
| A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells | Q35327308 | ||
| The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells | Q35329030 | ||
| Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation | Q35751954 | ||
| Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro | Q35767631 | ||
| Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model | Q35800497 | ||
| Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum | Q36079820 | ||
| Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor | Q36363861 | ||
| The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design | Q36547207 | ||
| IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner | Q36855263 | ||
| NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors | Q36890816 | ||
| Twelve immunotherapy drugs that could cure cancers | Q37118201 | ||
| Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model | Q37141874 | ||
| Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice | Q37204756 | ||
| A potential role for interleukin-15 in the regulation of human natural killer cell survival | Q37364381 | ||
| Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma | Q37557639 | ||
| Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model | Q37814208 | ||
| Strategies for the rapid construction of conditionally-replicating HSV-1 vectors expressing foreign genes as anticancer therapeutic agents | Q37818121 | ||
| Immunotherapy for SV40 T/t antigen-induced breast cancer by recombinant adeno-associated virus serotype 2 carrying interleukin-15 in mice | Q39389799 | ||
| The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon | Q39399591 | ||
| Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. | Q39430229 | ||
| Innate immune response of the human host to exposure with herpes simplex virus type 1: in vitro control of the virus infection by enhanced natural killer activity via interleukin-15 induction | Q39592514 | ||
| Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. | Q39852211 | ||
| How a cytokine is chaperoned through the secretory pathway by complexing with its own receptor: lessons from interleukin-15 (IL-15)/IL-15 receptor alpha | Q39978313 | ||
| Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits. | Q39995833 | ||
| Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action | Q40016459 | ||
| Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity | Q40041302 | ||
| Standardization of an orthotopic mouse brain tumor model following transplantation of CT-2A astrocytoma cells | Q40092939 | ||
| Soluble Interleukin IL-15Ralpha is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15. | Q40165758 | ||
| Membrane-bound and soluble IL-15/IL-15Ralpha complexes display differential signaling and functions on human hematopoietic progenitors. | Q40405349 | ||
| Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. | Q40464370 | ||
| Up-regulation of NK cytotoxic activity via IL-15 induction by different viruses: a comparative study | Q40924978 | ||
| A Clone of the MOCH-1 Glial Tumor in Culture: Multiple Phenotypes Expressed Under Different Environmental Conditions | Q41276897 | ||
| Ganglioside distribution in murine neural tumors | Q41600274 | ||
| Human cytomegalovirus TRS1 and IRS1 gene products block the double-stranded-RNA-activated host protein shutoff response induced by herpes simplex virus type 1 infection | Q42589554 | ||
| Treatment of hepatocellular carcinoma with adeno-associated virus encoding interleukin-15 superagonist | Q42830545 | ||
| Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal | Q42857041 | ||
| Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture | Q44460699 | ||
| Intralesional injection of herpes simplex virus 1716 in metastatic melanoma | Q44718611 | ||
| Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus | Q45745964 | ||
| Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity | Q45751042 | ||
| Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response | Q45869546 | ||
| NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer | Q45876380 | ||
| Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. | Q48727800 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Herpes simplex virus type 1 | Q655331 |
| P304 | page(s) | e81768 | |
| P577 | publication date | 2013-11-27 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1 | |
| P478 | volume | 8 |
| Q54248936 | Armed oncolytic viruses: A kick-start for anti-tumor immunity. |
| Q26752277 | Cancer immunotherapy: the beginning of the end of cancer? |
| Q27025330 | Emerging role of Natural killer cells in oncolytic virotherapy |
| Q34427647 | Going viral with cancer immunotherapy |
| Q56378150 | HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses |
| Q61809310 | IL-15 Generates IFN-γ-producing Cells Reciprocally Expressing Lymphoid-Myeloid Markers during Dendritic Cell Differentiation |
| Q40049630 | Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent |
| Q38848223 | Oncolytic Immunotherapy for Treatment of Cancer |
| Q64071725 | Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors |
| Q26862461 | Oncolytic virotherapy using herpes simplex virus: how far have we come? |
| Q92099101 | Oncolytic viruses: overcoming translational challenges |
| Q28072347 | Trial Watch-Oncolytic viruses and cancer therapy |
| Q27021951 | Trial Watch:: Oncolytic viruses for cancer therapy |
Search more.